Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
positive tags : Trial save search
Benitec Biopharma Reports Positive Interim Clinical Trial Data for First OPMD Subject Treated with BB-301 in Phase 1b/2a Study
Published: 2024-04-18 (Crawled : 12:00) - biospace.com/
BNTC | News | $6.82 42.08% 30.64% 3.5M
|
Health Technology
|
| O: 5.41%
H: 41.06%
C: 29.66%
bb-301 first positive biopharma for trial opmd study
Cerevel Therapeutics Announces Positive Topline Results for Tavapadon in Phase 3 Adjunctive Trial for People Living with Parkinson’s Disease
Published: 2024-04-18 (Crawled : 11:00) - globenewswire.com
CERE | News | $42.14 1.3% 1.33% 1.3M
|
Finance
|
| O: 0.78%
H: 0.0%
C: 0.0%
disease positive for topline parkinson’s trial therapeutics results living
Immutep Receives Positive Feedback from the Spanish Medicines Agency for Upcoming TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer
Published: 2024-04-17 (Crawled : 12:00) - globenewswire.com
IMMP | News | $2.2 -2.66% -2.73% 270K
|
Health Technology
|
| O: -6.87%
H: 0.0%
C: 0.0%
tacti-004 lung positive cancer cell for trial
Viracta Therapeutics Announces Positive Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial in Patients with Relapsed or Refractory Epstein-Barr Virus-Positive (EBV+) Peripheral T-Cell Lymphoma
Published: 2024-04-15 (Crawled : 12:00) - globenewswire.com
VIRX | $0.909 -2.91% -4.36% 79K
|
Manufacturing
|
| O: -12.71%
H: 0.97%
C: -24.27%
t-cell positive topline trial therapeutics results
TFF Pharmaceuticals Announces Additional Positive Data from the Tacrolimus Inhalation Powder (TFF TAC) Phase 2 Trial Following Oral Presentation at the ISHLT 44th Annual Late Breaking Clinical Science Abstract Sessions
Published: 2024-04-15 (Crawled : 11:00) - globenewswire.com
TFFP | $3.135 -3.26% -9.69% 26K
|
Health Technology
|
| O: 0.25%
H: 1.26%
C: -11.56%
tacrolimus presentation positive sessions pharmaceuticals trial
Syndax Presents Positive Pediatric Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at ASPHO Plenary Session
Published: 2024-04-08 (Crawled : 11:00) - prnewswire.com
SNDX | $20.49 -1.21% -1.47% 1.2M
|
Health Technology
|
| O: 3.35%
H: 0.0%
C: -1.34%
gment-101 positive leukemia trial
Positive Results from Phase 3 OPTIMIZE-1 Trial of Once Daily OCS-01 for the Treatment of Inflammation and Pain Following Cataract Surgery Presented at the 2024 American Society of Cataract and Refractive Surgery Annual Meeting
Published: 2024-04-08 (Crawled : 11:00) - biospace.com/
OCS | $11.78 -1.01% -0.76% 57K
|
n/a
|
| O: 0.36%
H: 0.18%
C: -2.76%
ocs-01 positive treatment for meeting trial results
Natera Announces Positive Surveillance Analysis from the Randomized Phase III IMvigor011 Trial in Muscle-Invasive Bladder Cancer
Published: 2024-04-05 (Crawled : 12:30) - biospace.com/
NTRA S | $87.28 -3.38% -3.6% 90
|
Health Services
|
| O: 2.12%
H: 4.35%
C: 2.25%
bladder positive cancer trial
Tempest Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications
Published: 2024-04-04 (Crawled : 12:00) - globenewswire.com
TPST | $3.17 -3.06% -2.83% 310K
|
Manufacturing
|
| O: 8.39%
H: 2.71%
C: -12.96%
tpst-1120 tumors positive cancer publication research communications trial advanced
Biora Therapeutics Achieves Positive Interim Results for Clinical Trial of BT-600, Advancing NaviCap™ Platform Development
Published: 2024-04-04 (Crawled : 12:00) - globenewswire.com
BIOR | $0.5995 -6.63% -7.02% 520K
|
Health Care and Social Assistan...
|
| O: 1.34%
H: 0.0%
C: -4.21%
bt-600 positive trial therapeutics results platform
Candel Therapeutics Announces Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer
Published: 2024-04-04 (Crawled : 12:00) - globenewswire.com
CADL | $5.46 0.37% 0.91% 730K
|
|
| O: 26.87%
H: 276.85%
C: 215.27%
can-2409 positive cancer pancreatic trial therapeutics
PMV Pharmaceuticals Announces First Patient Dosed in Global Tumor-Agnostic Phase 2 PYNNACLE Trial for Rezatapopt in TP53 Y220C-Positive Solid Tumors
Published: 2024-03-27 (Crawled : 12:00) - globenewswire.com
PMVP | $1.62 0.62% 0.62% 460K
|
Commercial Services
|
| O: -1.2%
H: 4.27%
C: 0.61%
tp53 first tumors pharmaceuticals global trial
Moderna Achieves Positive Interim Results from Phase 3 Trial of Next-Generation COVID-19 Vaccine
Published: 2024-03-26 (Crawled : 12:00) - biospace.com/
MRNA S | $102.0 -1.39% -1.4% 1.4M
|
Health Technology
|
| O: 1.29%
H: 0.0%
C: -3.93%
covid-19 vaccine positive trial results
Moleculin Announces Positive Interim Data in Annamycin MB-106 Phase 1B/2 AML Trial
Published: 2024-03-25 (Crawled : 14:00) - biospace.com/
MBRX | News | $4.5235 5.69% 6.75% 50K
|
Health Technology
|
| O: 5.18%
H: 0.0%
C: -12.5%
mb-106 positive aml trial
Astria Therapeutics Announces Positive Initial Proof-of-Concept Results from the ALPHA-STAR Phase 1b/2 Trial of STAR-0215 for HAE
Published: 2024-03-25 (Crawled : 14:00) - biospace.com/
ATXS | $10.54 -0.1% 0.09% 320K
|
Manufacturing
|
| O: 10.71%
H: 0.9%
C: -11.94%
star-0215 positive trial therapeutics results
LivaNova Announces a Positive Predictive Outcome of Trial Success in its OSPREY Clinical Study for Moderate to Severe Obstructive Sleep Apnea
Published: 2024-03-20 (Crawled : 19:00) - biospace.com/
LIVN | $52.76 1.72% 1.76% 430K
|
Health Technology
|
| O: 1.81%
H: 11.57%
C: 10.5%
success positive trial study
Femasys Announces Positive Topline Data from Pivotal Trial for its FDA-Cleared FemaSeed® for the Treatment of Infertility
Published: 2024-03-20 (Crawled : 12:00) - globenewswire.com
FEMY | News | $1.31 0.77% 0.38% 5.4K
|
Manufacturing
|
| O: -6.5%
H: 0.53%
C: -3.74%
femaseed positive treatment topline trial
Cerus Corporation Announces Positive Topline Results for the Phase 3 Clinical Trial of the INTERCEPT Blood System for Red Blood Cells in Cardiovascular Surgery Patients
Published: 2024-03-19 (Crawled : 15:00) - biospace.com/
CERS | News | $1.64 0.3% 610K
|
Health Technology
|
| O: 12.9%
H: 5.71%
C: -2.86%
corporation positive blood system topline trial cardiovascular results
Immuneering Announces Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors
Published: 2024-03-14 (Crawled : 11:00) - globenewswire.com
IMRX | $1.77 -4.84% -5.08% 160K
|
|
| O: -21.09%
H: 7.96%
C: -37.5%
tumors positive topline trial results
Crinetics Announces Positive Topline Results from Phase 2 Trial of Paltusotine for the Treatment of Carcinoid Syndrome
Published: 2024-03-12 (Crawled : 20:00) - globenewswire.com
CRNX | $43.01 -2.27% -2.34% 400K
|
Health Technology
|
| O: 0.81%
H: 2.03%
C: -1.41%
positive treatment topline trial results
Gainers vs Losers
| 58% | 42% |
Top 10 Gainers
ZCMD | $1.45 5.84% 49.63% 15M
|
Commercial Services
AULT | $0.2421 -7.7% 45.23% 16M
|
Manufacturing
XPON | News | $3.15 63.21% 33.9% 100K
|
EGOX | $0.036 12.15% 31.56% 32M
|
TIRX | $0.8 65.02% 25.95% 410K
|
VTNR 4 | $1.31 33.78% 25.82% 220K
|
Industrial Services
GDHG | $0.263 21.76% 25.34% 1.3M
|
TPET | $0.3279 -3.56% 23.57% 11M
|
n/a
HOLO | $2.95 31.7% 22.49% 37M
|
MTNB | $0.19 -1.04% 14.58% 950K
|
Health Technology
Your saved searches
Save your searches and get alerts when important news are released.